Trial Profile
Multi-institutional randomized Phase 2 trial of a treatment of nivolumab combined with stereotactic body radiotherapy for patients with unresectable or metastatic renal cell carcinoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NIVOSTRCC
- 25 Jan 2018 New trial record